RH-34 is a compound which acts as a potent and selective partial agonist for the 5-HT2A serotonin receptor subtype. It was derived by structural modification of the selective 5-HT2A antagonist ketanserin, with the 4-(p-fluorobenzoyl)piperidine moiety replaced by the N-(2-methoxybenzyl) pharmacophore found in such potent 5-HT2A agonists as NBOMe-2C-B and NBOMe-2C-I. This alteration was found to retain 5-HT2A affinity and selectivity, but reversed activity from an antagonist to a moderate efficacy partial agonist.
Legal status
RH-34 is a controlled substance in Hungary and Brazil.
See also
- 5-MeO-NBpBrT
- IHCH-7113
- Ketanserin
- Efavirenz
References


![H34Report 2020 [2] Hauptstraße 34 nächste Entwurfsphase](https://ellefeld.de/media/Default/09_H34/3_h34_2_sig_720x720.jpg)

